Tag Archive for: antibody-drug conjugates

With the investment in the plant, Daiichi Sankyo is looking to create new laboratories for its antibody drug conjugates used to develop and manufacture therapies for breast, lung and stomach cancers.

Ambrx is developing therapies that belong to the class of drugs called antibody drug conjugates (ADC), which are described by researchers as “guided missiles” to target cancer cells and minimize damage to healthy tissue.

At this year’s European Society for Medical Oncology, excitement topped 2022 levels on NSCLC and breast cancer innovation.

The deal would help boost AbbVie’s plans to expand into the cancer drug market as its top-selling product Humira, a rheumatoid arthritis treatment, faces fierce competition in the United States.

GSK said on that its blood cancer drug Blenrep had reached a key goal in a late-stage trial, as the British drugmaker looks to bolster its oncology business after a series of setbacks.

Looking beyond the coronavirus business, the company has renewed its focus on a growing development pipeline in oncology, which includes use of the mRNA technology pioneered in the vaccine as well as precision anti-cancer drugs from a class known as antibody-drug conjugates and therapies based on modified immune cells.

The move comes days after Merck said it would pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs in a deal that could be worth up to $22 billion for the Japanese firm.

The three drug candidates to be developed with Merck belong to the class known as antibody drug conjugates (ADC) and are in various stages of clinical development for the treatment of multiple solid cancer tumors.

The European Commission said the deal would not significantly reduce competition in the 27-country European Union nor would it have a negative impact on prices.

AstraZeneca said on its experimental precision drug had slowed the progression of a common type of breast cancer in a late-stage trial, a boost for the company after its shares fell in July on results from a separate trial of the same drug for lung cancer.